Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea Identifier:
First received: June 5, 2012
Last updated: August 31, 2016
Last verified: August 2016
The aim of this study is rate of acute graft-versus-host disease II-IV measured at day +365according to conventional criteria (Przepiorka et al. 1995) in patients with high risk non-Hodgkin lymphoma B subjects with Allogeneic Stem Cell Transplant

Condition Intervention Phase
B-Cell Lymphomas
Drug: Ofatumumab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea:

Primary Outcome Measures:
  • Rate of acute grade II-IV graft-versus-host disease at 1 year [ Time Frame: 5 years follow-up ] [ Designated as safety issue: Yes ]
    According to conventional criteria. This endpoint will be descriptively reported. Confidence intervals (95% bounds) will be provided. The rate will be analyzed in all patients enrolled at the clinical trial and that no major violation has been produced.

Secondary Outcome Measures:
  • To analyze the complete response rate after treatment. Further secondary outcomes as described in study summary [ Time Frame: 5 years follow up ] [ Designated as safety issue: Yes ]

Enrollment: 33
Study Start Date: May 2012
Estimated Study Completion Date: June 2020
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ofatumumab
Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
Drug: Ofatumumab
Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
Other Name: ARZERRA

Detailed Description:

In addition to above:

  • Rate of progression-free survival (PFS) at 12, 24, 36 and 60 months post-transplant defined as the time between the infusion of progenitors and the disease progression or death. Patients alive or in complete remission will be censored at the time of last follow up
  • Transplant-related mortality (TRM) at 12, 24, 36 and 60 months after transplantation, defined as any death not caused directly by lymphoma (any death caused by complications related to transplantation).
  • Overall survival (OS) defined as the time between infusion of progenitors and the patient's death from any cause. Alive Patients will be censored at the time of last follow-up
  • Incidence of chronic graft versus host disease (GVHD) wide at 1 and 5 years according to conventional criteria (Atkinson et al. 1989) and Filipovich et al. (BBMT, 2005).
  • Rate of event-free survival (DFS) defined as time interval between diagnosis of lymphoma and lymphoma progression or relapse or death if the above does not occur.
  • Successful graft implantation: is defined as:

    1. º: three consecutive days with absolute neutrophil count greater than 0.5 * 109 / L
    2. ° thrombocythemia exceeds 20 * 109 / L.
  • Reconstitution of the immune system: lymphocyte count populations CD20, CD3, CD4 and CD8 and immunoglobulinemia serum (days +100, 180, 360, 18 months and 24 months).
  • intercurrent infections. All sorts of infections (viral, fungal and bacterial)will be recorded
  • Safety assessment by the standards of Common Terminology Criteria for adverse events v. 4.0

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects who have given their informed consent before any study-specific procedures
  2. Histopathological diagnostic of NHL cell B CD 20 + B of different histologic subtypes:
  3. High risk CD +20 Lymphoma having at least one of the following characteristics:

    • Less than a partial remission after two courses of treatment
    • Relapse after autologous peripheral blood stem cell (PBSCT)
    • Evidence of measurable disease (With CT and PET or PET / CT) three months after PBSCT
    • Hematopoietic precursors improper count in patients with relapsed or partial remission after two treatment lines that prevent the realization of a PBSCT.
    • Patients after first relapse in RP after two lines of treatment in whom the probability of freedom from progression per year is very low due to risk factors such as: first CR less than 12 months after PBSCT low SLP, etc..
  4. Age between 18 and 65 years
  5. ECOG between 0 to 1 (Appendix III).
  6. Subjects who are HBgAG negative, anti-HBc positive and HBV DNA negative may be include in the study but must undergo HBV DNA monitoring
  7. Adequate lung Function
  8. Cardiac ejection greater than 40% as measured by scintigraphy or echocardiography.
  9. Adequate renal and hepatic function defined by the following biochemical parameters
  10. The disease status prior to transplantation had to be in place in accordance with the criteria of Revised Response Criteria for Malignant Lymphoma, Cheson 2007. CT and PET or PET / CT.
  11. Availability of a histocompatible donor (9 to 10/10 loci) family or unrelated
  12. Adults with ability to procreate must commit to use an effective method of birth control during the study treatment and at least 6 months.

Exclusion Criteria:

  1. Refractory disease at the time of transplantation
  2. Progressive disease at the time of transplantation.
  3. ECOG≤2
  4. Lymphoma associated with infection with human immunodeficiency virus (HIV).
  5. Test positive for HIV.
  6. Presence of anti-murine antibodies (HAMA) or (HACA).
  7. Treatment with any marketed or experimental drug administered not in a period between 5 terminal half-lives of clearance of therapy or 4 weeks before enrollment
  8. Participation in another interventional clinical trial.
  9. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy. This is generally required and may be excluded as applicable.
  10. Hepatitis B positive serology
  11. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg.
  12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb.
  13. Active liver or biliary disease (with exception of Gilbert's disease, cholelithiasis, metastases).
  14. Other past or current malignancy.
  15. Chronic infectious disease that requires ongoing treatment with systemic antibiotics, antifungal or antiviral drugs
  16. History of cerebrovascular disease active in the last 6 months or event with significant symptoms or sequelae.
  17. Clinically significant heart disease, such as unstable angina, acute myocardial infarction in the six months prior to inclusion, congestive heart failure (grades III-IV NYHA) and arrhythmia unless it is controlled by treatment, except for premature or disorders Mild driving.
  18. Concurrent medical disorder, uncontrolled and important, such as kidney disease, liver, digestive, endocrine, pulmonary, neurological, brain, psychiatric, or which in the opinion of the investigator may represent a risk to the patient
  19. Pregnancy or breastfeeding
  20. Women of childbearing potential, including those whose last menstrual period was one year prior to screening.
  21. Men unable or unwilling to use contraception
  22. Patients with hypersensitivity to fludarabine, melphalan, thiotepa, tacrolimus, sirolimus and / or any excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01613300

ICO-Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain, 08918
Hospital Clinic
Barcelona, Spain, 08036
Hospital Santa Creu i Sant Pau
Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Reina Sofia
Córdoba, Spain
H.U. 12 de Octubre,
Madrid, Spain
H.U. Gregorio Marañón,
Madrid, Spain
H.U. La Paz
Madrid, Spain
H. Morales Meseguer.
Murcia, Spain
Complejo Hospitalario Carlos Haya
Málaga, Spain, 29010
Hospital Son Espasses
Palma de Mallorca, Spain
H. Clinico de Salamanca
Salamanca, Spain
Hospital Virgen del Rocío
Sevilla, Spain, 41013
H. La Fe
Valencia, Spain
Sponsors and Collaborators
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Principal Investigator: Maria Dolores Caballero, MD Hospital Clinico de Salamanca
  More Information

Responsible Party: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea Identifier: NCT01613300     History of Changes
Other Study ID Numbers: GELTAMO-O-CRT-2011  2011-004729-29 
Study First Received: June 5, 2012
Last Updated: August 31, 2016
Health Authority: Spain: Spanish Agency of Medicines
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea:

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on October 21, 2016